Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vitrolife AB ( (SE:VITR) ) just unveiled an update.
Vitrolife AB announced a restructuring program for its genetic services business, aiming for annual savings of SEK 65 million by the end of Q3 2026. The program involves discontinuing certain genetic test lines and exiting low-profit markets, impacting 6% of the workforce and resulting in a SEK 5.4 billion goodwill impairment related to the Igenomix acquisition.
The most recent analyst rating on (SE:VITR) stock is a Buy with a SEK167.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.
More about Vitrolife AB
Vitrolife Group is a global provider of medical devices and genetic testing solutions, focusing on reproductive health. With a mission to improve treatment outcomes for patients, the company operates in over 125 countries, supported by 1,100 employees and headquartered in Gothenburg, Sweden.
Average Trading Volume: 142,659
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.75B
Find detailed analytics on VITR stock on TipRanks’ Stock Analysis page.